Trademark: THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Mark Identification
THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Click here to search for trademarks similar to THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY
We do not have any records of a proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY at this moment.
Click here to add a proof of use for THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Possible trademark infringements of THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Basic Information about THE INTRATUMORAL IMMUNOTHERAPY COMPANY
- Serial Number
- 90491212
- Filing Date
- 27 Jan 2021
- Mark Drawing Code
- 4
Classifications
Declare the trademark use of THE INTRATUMORAL IMMUNOTHERAPY COMPANY on the blockchain with WikiTrademarks.io.
- First use of THE INTRATUMORAL IMMUNOTHERAPY COMPANY anywhere
- THE INTRATUMORAL IMMUNOTHERAPY COMPANY was first used on 01 Nov 2020 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 6
- International Code
- 042
- US Codes
- 100; 101
Who owns THE INTRATUMORAL IMMUNOTHERAPY COMPANY?
1. Syncromune, Inc. Fort Lauderdale FL
Correspondent
- Jessica L. Rothstein
- Goodwin Procter LLP
- 620 Eighth Avenue
- New York NY 10018
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io